Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is study is to evaluate the safety and efficacy of cosibelimab in special populations with advanced cutaneous squamous cell carcinoma (CSCC). The name of the drug involved in this research study is: -cosibelimab (a type of an anti-PD-L1 antibody)
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent z historią przeszczepu nerki (przynajmniej 6 miesięcy przed rozpoczęciem badania)
- •Diagnoza pewnego rodzaju choroby krwi: przewlekły nowotwór myeloproliferacyjny, powolny chłoniak nieziarniczy lub szpiczak множественный
- •Potwierdzony histologicznie lub cytologicznie rak płaskonabłonkowy skóry
- •Rak nie poddający się operacji, radioterapii lub nawracający po poprzedniej operacji albo radioterapii
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 11, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Brigham and Women's Hospital
Boston, United States
Dana-Farber Cancer Institute
Boston, United States
Trial contact
Ann Silk, MD
Ann Silk, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/12/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.